American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1104-1114 , December 2008

The Association of Race With Erythropoietin Dose in Patients on Long-term Hemodialysis

Received 9 October 2007 ,Accepted 22 July 2008.

References 

  1. Keppel KG, Pearcy JN, Wagener DK. Trends in Racial and Ethnic-Specific Rates for the Health Status Indicators: United States, 1990-98 (Healthy People 2000 Stat Notes 1-16). Hyattsville, MD: National Center for Health Statistics; 2002;
  2. Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J Am Soc Nephrol. 2002;13:2363–2370
  3. Li S, McAlpine DD, Liu J, Li S, Collins AJ. Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther. 2004;11:5–13
  4. Owen WF. Racial differences in incidence, outcome, and quality of life for African-Americans on hemodialysis. Blood Purif. 1996;14:278–285
  5. Price DA, Owen WF. African-Americans on maintenance dialysis: A review of racial differences in incidence, treatment, and survival. Adv Ren Replace Ther. 1997;4:3–12
  6. Owen WF, Szczech LA, Frankenfield DL. Healthcare system interventions for inequality in quality: Corrective action through evidence-based medicine. J Natl Med Assoc. 2002;94(suppl 8):S83–S91
  7. Sehgal AR. Impact of quality improvement efforts on race and sex disparities in hemodialysis. JAMA. 2003;289:996–1000
  8. Collins AJ, Kasiske B, Herzog C, et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis. 2007;49(suppl 1):S16–S296
  9. Petronis KR, Carroll CE, Held PJ, Port FK. Effect of race on access to recombinant human erythropoietin in long-term hemodialysis patients. JAMA. 1994;271:1760–1763
  10. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF. Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis. 1999;34:721–730
  11. Lacson E, Teng M, Lazarus JM, Lew N, Lowrie E, Owen W. Limitations of the facility-specific standardized mortality ratio for profiling health care quality in dialysis. Am J Kidney Dis. 2001;37:267–275
  12. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–974
  13. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  14. Lazarus JM, Hakim RM. Dialysis facility ownership and epoetin dosing in hemodialysis patients: A dialysis provider's perspective. Am J Kidney Dis. 2007;50:366–370
  15. Yaqub MS, Leiser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease patients. Am J Nephrol. 2001;21:390–396
  16. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  17. Krishnan M, Adams E. Managing the anemia of end-stage renal disease after hospitalization. Nephrol Nurs J. 2004;31:541–544
  18. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  19. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996;334:420–425
  20. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: What is the evidence base?. Nephrol Dial Transplant. 2003;18(suppl 8):Sviii29–Sviii35
  21. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant. 1991;6:342–345
  22. Al Hilali N, Al Humoud H, Ninan VT, Nampoory MR, Puliyclil MA, Johny KV. Does parathyroid hormone affect erythropoietin therapy in dialysis patients?. Med Princ Pract. 2007;16:63–67
  23. Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant. 2002;17(suppl 5):S28–S31

 Originally published online as doi:10.1053/j.ajkd.2008.07.026 on September 29, 2008.

PII: S0272-6386(08)01223-7

doi: 10.1053/j.ajkd.2008.07.026

American Journal of Kidney Diseases
Volume 52, Issue 6 , Pages 1104-1114 , December 2008

Article Tools

* Image Usage & Resolution